These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 30780828)

  • 1. Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use.
    Ampudia-Blasco FJ; Gómez CC; Claramunt XC; Alegría JG; Gimeno EJ; Bravo JJM; Raya PM; Pérez JN; Domingo MP
    Expert Rev Endocrinol Metab; 2010 Nov; 5(6):799-807. PubMed ID: 30780828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.
    Dharmalingam M; Sriram U; Baruah MP
    Indian J Endocrinol Metab; 2011 Jan; 15(1):9-17. PubMed ID: 21584160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes.
    Hribal ML; Sesti G
    Expert Rev Endocrinol Metab; 2010 Jul; 5(4):495-505. PubMed ID: 30780808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide Effect and Action in Diabetes (LEAD™) trial.
    Madsbad S
    Expert Rev Endocrinol Metab; 2009 Mar; 4(2):119-129. PubMed ID: 30780853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
    Joffe D
    Am J Health Syst Pharm; 2010 Aug; 67(16):1326-36. PubMed ID: 20689121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.
    Rigato M; Fadini GP
    Diabetes Metab Syndr Obes; 2014; 7():107-20. PubMed ID: 24672252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide: clinical pharmacology and considerations for therapy.
    Sisson EM
    Pharmacotherapy; 2011 Sep; 31(9):896-911. PubMed ID: 21923591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies.
    McGill JB
    Postgrad Med; 2009 May; 121(3):16-25. PubMed ID: 19491536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC; Conner C; Hammer M
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity.
    Hasanzad M; Sarhangi N; Nikfar S; Ostad SN; Aghaei Meybodi HR
    J Diabetes Metab Disord; 2020 Dec; 19(2):1863-1872. PubMed ID: 33520865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.